Liquid biopsy developer OncoCell MDx raises $22.2M in Series B round
The company plans to launch its prostate cancer test next year and has several papers it will to submit to journals in the next four to six months.
OncoCell MDx
The company plans to launch its prostate cancer test next year and has several papers it will to submit to journals in the next four to six months.